These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 21894646)

  • 1. Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?
    Dawson J; Walters M
    Br J Clin Pharmacol; 2006 Dec; 62(6):633-44. PubMed ID: 21894646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uric acid reduction: a new paradigm in the management of cardiovascular risk?
    Dawson J; Quinn T; Walters M
    Curr Med Chem; 2007; 14(17):1879-86. PubMed ID: 17627523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uric acid lowering therapy in cardiovascular diseases.
    Volterrani M; Iellamo F; Sposato B; Romeo F
    Int J Cardiol; 2016 Jun; 213():20-2. PubMed ID: 26386814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uric acid: role in cardiovascular disease and effects of losartan.
    Alderman M; Aiyer KJ
    Curr Med Res Opin; 2004 Mar; 20(3):369-79. PubMed ID: 15025846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xanthine Oxidase and its Role as Target in Cardiovascular Disease: Cardiovascular Protection by Enzyme Inhibition?
    Schuchardt M; Herrmann J; Tolle M; van der Giet M
    Curr Pharm Des; 2017; 23(23):3391-3404. PubMed ID: 28413972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperuricaemia and vascular risk: the debate continues.
    Landolfo M; Borghi C
    Curr Opin Cardiol; 2019 Jul; 34(4):399-405. PubMed ID: 30925517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.
    Bomalaski JS; Clark MA
    Curr Rheumatol Rep; 2004 Jun; 6(3):240-7. PubMed ID: 15134605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperuricemia and adverse outcomes in cardiovascular disease: potential for therapeutic intervention.
    Gavin AR; Struthers AD
    Am J Cardiovasc Drugs; 2003; 3(5):309-14. PubMed ID: 14728064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study.
    Oyama J; Tanaka A; Sato Y; Tomiyama H; Sata M; Ishizu T; Taguchi I; Kuroyanagi T; Teragawa H; Ishizaka N; Kanzaki Y; Ohishi M; Eguchi K; Higashi Y; Yamada H; Maemura K; Ako J; Bando YK; Ueda S; Inoue T; Murohara T; Node K;
    Cardiovasc Diabetol; 2016 Jun; 15():87. PubMed ID: 27317093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperuricemia and endothelial function: From molecular background to clinical perspectives.
    Maruhashi T; Hisatome I; Kihara Y; Higashi Y
    Atherosclerosis; 2018 Nov; 278():226-231. PubMed ID: 30326405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paeonia × suffruticosa Andrews leaf extract and its main component apigenin 7-O-glucoside ameliorate hyperuricemia by inhibiting xanthine oxidase activity and regulating renal urate transporters.
    Zhang Y; Li Y; Li C; Zhao Y; Xu L; Ma S; Lin F; Xie Y; An J; Wang S
    Phytomedicine; 2023 Sep; 118():154957. PubMed ID: 37478683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperuricemia and cardiovascular disease risk.
    Borghi C; Verardi FM; Pareo I; Bentivenga C; Cicero AF
    Expert Rev Cardiovasc Ther; 2014 Oct; 12(10):1219-25. PubMed ID: 25192804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure.
    Borghi C; Palazzuoli A; Landolfo M; Cosentino E
    Heart Fail Rev; 2020 Jan; 25(1):43-51. PubMed ID: 31745840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allopurinol as a therapeutic option in cardiovascular disease.
    Okafor ON; Farrington K; Gorog DA
    Pharmacol Ther; 2017 Apr; 172():139-150. PubMed ID: 27916655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Could uric acid reduction by specific xanthine oxidase inhibition improve vascular function and reduce cardiovascular risk?
    Skeete J; Ridley E; DiPette DJ
    J Clin Hypertens (Greenwich); 2019 Nov; 21(11):1721-1723. PubMed ID: 31556222
    [No Abstract]   [Full Text] [Related]  

  • 16. [Serum uric acid--a cardiovasular risk factor?].
    Alderman M; Redfern JS
    Ther Umsch; 2004 Sep; 61(9):547-52. PubMed ID: 15493113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic hyperuricemia, uric acid deposit and cardiovascular risk.
    Grassi D; Ferri L; Desideri G; Di Giosia P; Cheli P; Del Pinto R; Properzi G; Ferri C
    Curr Pharm Des; 2013; 19(13):2432-8. PubMed ID: 23173592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Uric acid--more deleterious than we thought?].
    Høieggen A; Os I; Kjeldsen SE
    Tidsskr Nor Laegeforen; 2005 May; 125(10):1330-2. PubMed ID: 15909004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of anti-inflammatory therapies, xanthine oxidase inhibitors and other urate-lowering therapies on cardiovascular diseases in gout.
    Richette P; Frazier A; Bardin T
    Curr Opin Rheumatol; 2015 Mar; 27(2):170-4. PubMed ID: 25594854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum uric acid and the risk of cardiovascular and renal disease.
    Borghi C; Rosei EA; Bardin T; Dawson J; Dominiczak A; Kielstein JT; Manolis AJ; Perez-Ruiz F; Mancia G
    J Hypertens; 2015 Sep; 33(9):1729-41; discussion 1741. PubMed ID: 26136207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.